Central pontine myelinolysis medical therapy: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Central pontine myelinolysi}} | {{Central pontine myelinolysi}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{MMJ}} | ||
==Overview== | ==Overview== | ||
Latest revision as of 20:38, 7 July 2020
Template:Central pontine myelinolysi Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamadmostafa Jahansouz M.D.[2]
Overview
Treatment of patients with central pontine myelinolysis is mainly supportive because once the osmotic demyelination has begun, there is no cure or specific treatment. Alcoholic patients should receive vitamin supplementation including vitamin B6, B9, and B12 and evaluation of their nutritional status.
Medical Therapy
Treatment of patients with central pontine myelinolysis is mainly supportive because once the osmotic demyelination has begun, there is no cure or specific treatment.[1][2]
Alcoholic patients should receive vitamin supplementation including vitamin B6, B9 and B12 and evaluation of their nutritional status.[3]
References
- ↑ Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D; et al. (2014). "Clinical practice guideline on diagnosis and treatment of hyponatraemia". Eur J Endocrinol. 170 (3): G1–47. doi:10.1530/EJE-13-1020. PMID 24569125.
- ↑ Lampl C, Yazdi K (2002). "Central pontine myelinolysis". Eur Neurol. 47 (1): 3–10. doi:10.1159/000047939. PMID 11803185.
- ↑ Kleinschmidt-DeMasters BK, Norenberg MD (1981). "Rapid correction of hyponatremia causes demyelination: relation to central pontine myelinolysis". Science. 211 (4486): 1068–70. doi:10.1126/science.7466381. PMID 7466381.